Nintedanib for treating progressive fibrosing interstitial lung diseases

2.1 Nintedanib (Ofev, Boehringer Ingelheim) is indicated in adults for the treatment of chronic fibrosing interstitial lung diseases with a progressive phenotype.

2.2 The dosage schedule is available in the summary of product characteristics.

2.3 The price of nintedanib is £2,151.10 per pack of 60 capsules, each containing 150 mg (excluding VAT; BNF online accessed July 2021). The company has a commercial arrangement. This makes nintedanib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.